Acta Medica Iranica 2018. 56(8):498-507.

Pharmacological Profile for the Contribution of NO/cGMP Pathway on Chlorpheniramine Antidepressant-Like Effect in Mice Forced Swim Test
Saeed Shakiba, Nazanin Rajai, Mehdi Qaempanah, Nazgol‐Sadat Haddadi, Abbas Norouzi-Javidan, Reyhaneh Akbarian, Sattar Ostadhadi, Ahmad-Reza Dehpour

Abstract


Chlorpheniramine, a first-generation antihistamine, is widely used for allergic reactions. Previous studies showed the interaction between antidepressant activity and nitric oxide and cyclic guanosine monophosphate (NO/cGMP) pathway. Thus, we aimed to assess the possible involvement of NO/cGMP pathway in this effect using forced swim test (FST) in male mice. To evaluate the locomotor activity and immobility time, we performed open field test (OFT) and FST on each mouse. Chlorpheniramine was administered intraperitoneally (i.p.) (0.1, 0.3, 1, 10 mg/kg) 30 minutes before FST. To assess the involvement of NO/cGMP pathway, a non-selective nitric oxide synthase (NOS) inhibitor, L-NAME (10mg/kg, i.p.), a selective inducible NOS (iNOS) inhibitor, aminoguanidine (50 mg/kg, i.p.), a selective neural NOS (nNOS) inhibitor, 7-nitroindazole (7-NI, 30 mg/kg, i.p.), a NO precursor, L-arginine (750 mg/kg, i.p.) and a selective phosphodiesterase-5 (PDE-5) inhibitor, sildenafil (5 mg/kg, i.p.) was co-administered with chlorpheniramine. Chlorpheniramine significantly decreased the immobility time at doses of 1mg/kg (P<0.01) and 10 mg/kg (P<0.001). Administration of L-NAME (P<0.01) and 7-NI enhanced the anti-immobility activity of chlorpheniramine (P<0.001), while aminoguanidine did not have any significant effects on the immobility time (P>0.05). Moreover, pretreatment with L-arginine (P<0.01) and sildenafil (P<0.001) significantly reduced the anti-immobility effect of chlorpheniramine. These treatments did not alter the locomotor activity of mice in OFT. Our results revealed that the antidepressant-like effect of chlorpheniramine is mediated through inhibition of NO/cGMP pathway.


Keywords


Chlorpheniramine; Nitric oxide; Cyclic guanosine monophosphate; Forced swim test; Mice

Full Text:

PDF

References


Kessler, R.C., K.R. Merikangas, and P.S. Wang, Prevalence, comorbidity, and service utilization for mood disorders in the United States at the beginning of the twenty-first century. Annu Rev Clin Psychol, 2007. 3: p. 137-58.

Berton, O. and E.J. Nestler, New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci, 2006. 7(2): p. 137-51.

Cakmakci, E., et al., Percutaneous liver biopsies guided with ultrasonography: a case series. Iran J Radiol, 2013. 10(3): p. 182-4.

Arroll, B., et al., Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: a meta-analysis. Ann Fam Med, 2005. 3(5): p. 449-56.

Lidbrink, P., G. Jonsson, and K. Fuxe, The effect of imipramine-like drugs and antihistamine drugs on uptake mechanisms in the central noradrenaline and 5-hydroxytryptamine neurons. Neuropharmacology, 1971. 10(5): p. 521-530.

Shishido, S., R. Oishi, and K. Saeki, In vivo effects of some histamine H1-receptor antagonists on monoamine metabolism in the mouse brain. Naunyn-Schmiedeberg's archives of pharmacology, 1991. 343(2): p. 185-189.

Tatsumi, M., et al., Pharmacological profile of antidepressants and related compounds at human monoamine transporters. European Journal of Pharmacology, 1997. 340(2): p. 249-258.

Onodera, K., et al., Neuropharmacology of the histaminergic neuron system in the brain and its relationship with behavioral disorders. Progress in neurobiology, 1994. 42(6): p. 685-702.

Goodwin, R.D., Panic disorder treated with the antihistamine chlorpheniramine. Annals of Allergy, Asthma & Immunology, 2003. 90(3): p. 361-362.

Aslanian, R., et al., Identification of a dual histamine H1/H3 receptor ligand based on the H1 antagonist chlorpheniramine. Bioorg Med Chem Lett, 2003. 13(12): p. 1959-61.

Hirano, S., et al., Effects of histamine H 1 receptor antagonists on depressive-like behavior in diabetic mice. Pharmacology Biochemistry and Behavior, 2006. 83(2): p. 214-220.

Rogoz, Z., G. Skuza, and H. Sowinska, Effects of antihistaminic drugs in tests for antidepressant action. Pol J Pharmacol Pharm, 1981. 33(3): p. 321-35.

Hirano, S., et al., Involvement of dopamine D1 receptors and alpha1-adrenoceptors in the antidepressant-like effect of chlorpheniramine in the mouse tail suspension test. Eur J Pharmacol, 2007. 562(1-2): p. 72-6.

Kurauchi, Y., et al., Midbrain dopaminergic neurons utilize nitric oxide/cyclic GMP signaling to recruit ERK that links retinoic acid receptor stimulation to up‐regulation of BDNF. Journal of neurochemistry, 2011. 116(3): p. 323-333.

Klejbor, I., et al., The relationships between neurons containing dopamine and nitric oxide synthase in the ventral tegmental area. Folia Histochemica et Cytobiologica, 2004. 42(2): p. 83-87.

Surmeier, D.J., et al., Modulation of calcium currents by a D 1 dopaminergic protein kinase/phosphatase cascade in rat neostriatal neurons. Neuron, 1995. 14(2): p. 385-397.

Förstermann, U. and W.C. Sessa, Nitric oxide synthases: regulation and function. European heart journal, 2012. 33(7): p. 829-837.

Denninger, J.W. and M.A. Marletta, Guanylate cyclase and the .NO/cGMP signaling pathway. Biochim Biophys Acta, 1999. 1411(2-3): p. 334-50.

Harkin, A.J., et al., Nitric oxide synthase inhibitors have antidepressant-like properties in mice. 1. Acute treatments are active in the forced swim test. Eur J Pharmacol, 1999. 372(3): p. 207-13.

Rosa, A.O., et al., Involvement of NMDA receptors and L-arginine-nitric oxide pathway in the antidepressant-like effects of zinc in mice. Behav Brain Res, 2003. 144(1-2): p. 87-93.

Ostadhadi, S., et al., Pharmacological evidence for the involvement of the NMDA receptor and nitric oxide pathway in the antidepressant-like effect of lamotrigine in the mouse forced swimming test. Biomedicine & Pharmacotherapy, 2016. 82: p. 713-721.

Ostadhadi, S., et al., Antidepressant effect of pramipexole in mice forced swimming test: A cross talk between dopamine receptor and NMDA/nitric oxide/cGMP pathway. Biomedicine & Pharmacotherapy, 2016. 81: p. 295-304.

Haj-Mirzaian, A., et al., Involvement of nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of tropisetron and ondansetron in mice forced swimming test and tail suspension test. European Journal of Pharmacology, 2016. 780: p. 71-81.

Khan, M.I., et al., The involvement of NMDA receptor/NO/cGMP pathway in the antidepressant like effects of baclofen in mouse force swimming test. Neuroscience letters, 2016. 612: p. 52-61.

Ostadhadi, S., et al., Involvement of NO/cGMP pathway in the antidepressant-like effect of gabapentin in mouse forced swimming test. Naunyn-Schmiedeberg's archives of pharmacology, 2016. 389(4): p. 393-402.

Ostadhadi, S., et al., Involvement of NMDA receptors and l-arginine/nitric oxide/cyclic guanosine monophosphate pathway in the antidepressant-like effects of topiramate in mice forced swimming test. Brain research bulletin, 2016. 122: p. 62-70.

in Guide for the Care and Use of Laboratory Animals. 2011: Washington (DC).

Turner, P.V., et al., Administration of substances to laboratory animals: routes of administration and factors to consider. J Am Assoc Lab Anim Sci, 2011. 50(5): p. 600-13.

Ostadhadi, S., et al., Involvement of opioid system in antidepressant-like effect of the cannabinoid CB1 receptor inverse agonist AM-251 after physical stress in mice. Clin Exp Pharmacol Physiol, 2016. 43(2): p. 203-12.

Khaloo, P., et al., Lithium attenuated the behavioral despair induced by acute neurogenic stress through blockade of opioid receptors in mice. Biomedicine & Pharmacotherapy, 2016. 83: p. 1006-1015.

Haj-Mirzaian, A., et al., Evidence for the involvement of NMDA receptors in the antidepressant-like effect of nicotine in mouse forced swimming and tail suspension tests. Psychopharmacology (Berl), 2015. 232(19): p. 3551-61.

Porsolt, R.D., A. Bertin, and M. Jalfre, Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther, 1977. 229(2): p. 327-36.

Kordjazy, N., et al., Involvement of N-methyl-d-aspartate receptors in the antidepressant-like effect of 5-hydroxytryptamine 3 antagonists in mouse forced swimming test and tail suspension test. Pharmacology Biochemistry and Behavior, 2016. 141: p. 1-9.

Kaster, M.P., et al., Involvement of nitric oxide-cGMP pathway in the antidepressant-like effects of adenosine in the forced swimming test. Int J Neuropsychopharmacol, 2005. 8(4): p. 601-6.

Dringenberg, H.C., et al., Increased levels of extracellular dopamine in neostriatum and nucleus accumbens after histamine H1 receptor blockade. Naunyn-Schmiedeberg's archives of pharmacology, 1998. 358(4): p. 423-429.

Fujisaki, Y., Y. Itoh, and R. Oishi, In vivo evidence for a lack of central effect of ebastine, an antihistaminic agent, in rats: a microdialysis study. The Japanese Journal of Pharmacology, 2002. 90(4): p. 353-356.

Hirano, S., et al., Involvement of dopamine D1 receptors and α1-adrenoceptors in the antidepressant-like effect of chlorpheniramine in the mouse tail suspension test. European Journal of Pharmacology, 2007. 562(1–2): p. 72-76.

Heiberg, I.L., G. Wegener, and R. Rosenberg, Reduction of cGMP and nitric oxide has antidepressant-like effects in the forced swimming test in rats. Behavioural brain research, 2002. 134(1): p. 479-484.

Harkin, A., et al., Nitric oxide synthase inhibitors augment the effects of serotonin re-uptake inhibitors in the forced swimming test. European Neuropsychopharmacology, 2004. 14(4): p. 274-281.

Wegener, G., V. Volke, and R. Rosenberg, Endogenous nitric oxide decreases hippocampal levels of serotonin and dopamine in vivo. British journal of pharmacology, 2000. 130(3): p. 575-580.

Hartell, N.A., Inhibition of cGMP breakdown promotes the induction of cerebellar long-term depression. J Neurosci, 1996. 16(9): p. 2881-90.


Refbacks

  • There are currently no refbacks.


Creative Commons Attribution-NonCommercial 3.0

This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.